Polymeric prodrugs combining immunomodulation and blockade of immune checkpoint inhibitors acting as an endogenous vaccine for synergistic therapy of tumors
Contractor: Institute of Macromolecular Chemistry of the CAS, v. v. i.; Institute of Microbiology of the CAS, v. v. i.
Principal investigator: Chytil Petr; Šírová Milada
Research years: 2017-2019
Synthesis, characterization and biological evaluation of HPMA-based tumor-targeted polymeric conjugates carrying cytostatics (doxorubicin, docetaxel) simultaneously with immunostimulatory agents and/or agents blocking immune checkpoint inhibitors. Identification of key mechanisms orchestrating the immune response to immunotherapy.